Global Health Q2 profit up 21% YoY; to expand Mumbai hospital to 750 beds

Global Health Ltd, which operates Medanta hospitals, reported its second quarter results on Friday, November 7, with a 21.1% year-on-year rise in consolidated net profit to ₹158.4 crore, compared with ₹130.8 crore in the same period last year.

The company's Q2FY26 revenue grew 14.9% YoY to ₹1,099 crore, while EBITDA inched up 1.1% to ₹230.8 crore.

However, the EBITDA margin declined to 21% from 23.8% a year ago, reflecting higher operating costs.

The company’s board of directors also approved expanding

the planned capacity of its upcoming Mumbai hospital from 500 to 750 beds, following additional FSI approval from the Mumbai Housing and Area Development Authority (MHADA).

The board also cleared the acquisition of 30 residential flats near the Mumbai site for ₹85 crore to accommodate clinicians and key staff. With these changes, the total project cost for the Mumbai hospital has been revised upward to ₹1,530 crore from ₹1,200 crore earlier.

Additionally, on November 6, the board of directors of GHL Pharma & Diagnostic Private Ltd, a wholly-owned subsidiary of Global Health, accepted the resignation of Rajdeep Panwar, Director and Manager of GHL Pharma. His last working day will be December 28, 2025.

Shares of Global Health Ltd ended lower on Friday, November 7, by 1.38% at ₹1,263.00 on the NSE.

Also Read: Trent Q2 Results: Tata Group retailer posts steady profit growth, revenue up 16% YoY